http://houstonpathologists.org/images/Brochure.pdf
There have many advances and paradigm shifts in pulmonary pathology and medicine, especially
lung cancer, over the past few years. These include:
(1) New targeted therapies for lung cancer and associated biomarkers, including new lung
cancer biomarker guidelines under development by the College of American Pathologists.,
The International Association for the Study of Lung Cancer and the Association for
Molecular Pathology .
(2) New pathologic classification for adenocarcinoma of the lung proposed by the
International Association for the Study of Lung Cancer, the American Thoracic Society
and the European Respiratory Society.
(3) New staging protocol for lung cancer by the American Joint Committee on Cancer, the
International Union for Cancer Control and the College of American Pathologists.
(4) New guidelines for the diagnosis of diffuse malignant mesothelioma.
(5) New guidelines for the pathologic and clinical diagnosis and management of idiopathic
pulmonary fibrosis by the American Thoracic Society, the European Respiratory Society,
the Japanese Respiratory Society, the Latin American Thoracic Society, the Society of
Thoracic Radiology and the Pulmonary Pathology Society.
(6) Development of new pathology imaging techniques for the in-vivo microscopic-level
diagnosis of pulmonary diseases
Saturday, April 28:
7:45-8:00 am Welcome-Philip Cagle, M.D.
8:00-8:45 am Proposed New Classification of Lung Cancer
Keith Kerr, M.D.
8:45-9:30 am Dilemmas in Lung Cancer Staging
Sanja Dacic, M.D., Ph.D.
9:30-10:15 am Benign Tumors and Tumor-Like Conditions of the Lung
Alain Borczuk, M.D.
10:15-10:45 am Break
10:45-11:30 am Update on Mesothelioma
Lucian Chirieac, M.D.
11:30-12:00 pm Clinical Genotyping of Lung Cancer: Beyond EGFR and EML4-ALK,
Beyond Adenocarcinoma
Marc Ladanyi, M.D.
12:00-12:30 pm Role of Cytopathology in the Molecular Diagnostics and Targeted
Therapy of Lung Cancer
Maureen Zakowski, M.D.
12:30-1:00 pm Lunch
1:30-2:15 pm Separation of Benign versus Malignant Mesothelial Proliferations
Andrew Churg, M.D.
2:15-3:00 pm Update on Idiopathic Interstitial Pnuemonias
Thomas Colby, M.D.
3:00-3:30 pm Break
3:30-4:15 pm Pulmonary Pathology of the Rheumatic Diseases
Kevin Leslie, M.D.
4:15-5:00 pm The Changing Role of Pathology in Managing Patients with Unexplained
Diffuse Lung Disease
Jeffrey Myers, M.D.
5:00-5:30 pm Panel Discussion
5:30 pm Adjournment-Philip T. Cagle, M.D.
Sunday, April 29:
7:45-8:00 am Welcome-Philip Cagle, M.D.
8:00-8::30 am Worldwide Overview of the Current Status of Lung Cancer Diagnosis and
Treatment
Paul Bunn, M.D.
8:30-9:00 am EGFR, ALK and KRAS Molecular Testing in Lung Adenocarcinoma: Why,
When and How
Neal I. Lindeman, M.D.
9:00-9:30 am Treatment of ALK-Positive NSCLC
Yung-Jue Bang, M.D.
9:30-10:00 am Strategies to Overcome Resistance to EGFR Target Therapies
Geoffrey R. Oxnard, M.D.
10:00-10:30 am Break
10:30-11:00 am Cryobiopsy in Pulmonary Diseases
Jurgen Hetzel, M.D.
11:00-11:30 am Advancing Personalized Cancer Medicine in Lung Cancer
Laura MacConaill, M.D.
11:30-12:30 pm Lunch
12:30-1:00 pm Volumetric Optical Frequency Domain Imaging of Lung Pathology:
Improving Biopsy Sampling and Evaluation
Lida P. Hariri, M.D., Ph.D.
1:00-1:30 pm Lung Cancer Differential Diagnosis by Label-Free, Molecular Vibrational
Imaging
Stephen T. C. Wong, Ph.D., P.E.
1:30-2:00 pm Screening for Lung Cancer: Who Should be Screened?
James Jett, M.D.
2:00-2:30 pm Molecular Pathology of Lung Cancer: Changes in Prevention and
Therapy Paradigms
Ignacio Wistuba, M.D.
2:30-3:00 pm Panel Discussion
3:00 pm Adjournment-Philip T. Cagle, M.D.
No comments:
Post a Comment